Özet:

Introduction. Psoriasis is an immune-mediated inflammatory skin disease. Since the use of therapeutic agents is often hampered by low efficacy and/or adverse effect profile, the presence of comorbid pathology, it is necessary to develop new therapeutic approaches for psoriasis. The objective of the study was to evaluate the clinical and laboratory efficacy of rosuvastatin in the treatment of patients with chronic plaque psoriasis. Material and methods. The study involved 52 patients with mild and moderate psoriasis, aged 45-64 years. The blood serum level of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and vascular endothelial growth factor (VEGF) were determined by immunoassay analysis. The serum lipid profile was also determined. Patients were divided into two groups, depending on the method of therapy. Patients of the 1st group received a combination therapy – rosuvastatin, topical corticosteroids (TCS) or phototherapy, patients of the 2nd group were prescribed only TCS or phototherapy. Results. The clinical improvement of psoriasis is noted under the influence of combination therapy. The PASI (Psoriatic Area and Severity Index) score decreased in 3 months by 68.2%. A marked decrease in the level of IL-6, hs-CRP after 1 month was noted, less significant VЕGF relative to the results before therapy. Lipid metabolism indices changed reliably only at the end of the 3rd month – the levels of TC and LDL-C were reduced. Conclusions. The use of rosuvastatin in the combination therapy of patients with psoriasis increases the effectiveness of treatment, helps to reduce the level of inflammatory markers, proangiogenic growth factor and normalize blood lipid spectrum. Keywords: psoriasis, endothelial dysfunction markers, treatment, statins.

Anahtar Kelimeler: